The Conversation on MSN6d
Ozempic And Other GLP-1s Show Promise With 42 Conditions — But There Are Still Big RisksSeveral years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
The ambitious plans aim to secure medicine supply, accelerate innovation, strengthen clinical research, and reinforce IP ...
The new EU compass could support small companies to grow their market share across Europe, assisted by fewer regulatory ...
Dosimetry is integral to informed implementation of radiopharmaceutical therapies, enabling personalized treatment planning ...
NorthStar, a leading provider of anesthesia care nationwide, is pleased to announce key changes to its executive leadership team as part of its strategy to continue driving the highest quality ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
If the U.S. slaps a 25% tariff on goods from Canada, that means that the U.S. importer must pay 25% more for the goods he ...
AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...
Scientists led by the Institute of Nanotechnology in Italy, in collaboration with the ESRF, the European ... the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead ...
A consistent stream of supply issues has disrupted deliveries of vital medicines – from hormone replacement therapy and ...
The latest Commission agenda tentatively schedules the Act for release on 11 March - exactly 100 days after the new ... European Patients Forum (EPF), together with EPHA members of the Critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback